Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support

CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions,

Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash,

Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product